# A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK

> **NCT05357820** · PHASE1 · COMPLETED · sponsor: **Nuvation Bio Inc.** · enrollment: 56 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** AB-106, Itraconazole
- **DRUG:** AB-106, Rifampicin

## Key facts

- **NCT ID:** NCT05357820
- **Lead sponsor:** Nuvation Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-19
- **Primary completion:** 2021-12-03
- **Final completion:** 2021-12-03
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2024-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05357820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05357820, "A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05357820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*